OTC医薬品 - 世界市場の考察、競合情勢、市場予測（2030年）

世界のOTC医薬品の市場規模は、2023年に1,511億5,000万米ドル、2030年までに2,130億8,000万米ドルに達し、2024年～2030年の予測期間にCAGRで5.93％の成長が見込まれます。市場は、鎮痛薬の需要拡大につながる痛みをもたらすさまざまな適応症の急増などの多くの理由により製品需要が爆発的に増加しています。さらに、胃腸疾患の流行も、OTC胃腸薬の成長に寄与している主な要因です。上記の要因に加えて、さまざまな医薬品の処方からOTCへの急速な切り替えも、2024年～2030年の予測期間における市場の成長動向の確立に重要な役割を果たすと見込まれます。

OTC医薬品の市場力学

OTC医薬品市場の主な成長促進要因の1つは、関節炎、腰痛、線維筋痛症などの筋骨格系に影響を及ぼすさまざまなモダリティの増加による鎮痛薬の使用の急増であり、その他のにも月経痛、頭痛などの適応症があります。例えば、Rheumatoid Arthritis Network（2023）によると、2022年に世界中で3億5,000万人が関節炎に苦しんでいます。さらに、National Health Service UK（2023）によると、世界中の20人に1人が線維筋痛症に罹患しています。鎮痛薬は、特に痛みを和らげることを目的とした薬の一分類です。関節炎の場合、アセトアミノフェン（米国ではタイレノール）のような特定のOTC鎮痛薬が積極的に消費されています。その他のOTC医薬品の鎮痛薬には、イブプロフェンやナプロキセンナトリウムなどがあります。鎮痛薬の他に、OTC医薬品のもう1つの人気カテゴリには解熱剤があり、アセトアミノフェン、イブプロフェン、デキシブポルフェンなどが含まれます。筋骨格系疾患の有病率の増加や疼痛管理へのニーズの高まりを考慮すると、今後数年間にOTC鎮痛薬の需要が増加し、2024年～2030年の予測期間にOTC医薬品市場全体を牽引することが見込まれます。

OTC医薬品への需要の増加のもう1つの大きな要因は、世界中で意図しない妊娠の患者が急増していることであり、このことが予測期間にOTC緊急避妊薬の需要に影響を与える見込みです。例えば、世界保健機関（WHO）が提供したデータ（2023）によると、世界中の低中所得国に住む400万人の女性が毎年意図しない妊娠をしています。これは、世界全体で毎年2,500万件の安全でない中絶と4万7,000人の妊産婦死亡につながっています。現代の避妊法は、意図しない妊娠を防ぐ上で重要な役割を担っています。国連経済社会局（2019）の統計では、約9億2,200万人の生殖年齢にある女性（またはそのパートナー）がさまざまな製品からなる避妊法を使用しており、その中でも緊急避妊薬は、意図しない妊娠を避けるためのもっとも一般的で信頼できる情報源の1つであると述べられています。さらに、COVID-19パンデミックにより、子宮内避妊機器や避妊パッチなど、その他の避妊方法として利用可能な代替品へのアクセスが困難になったため、利用者の間でOTC緊急避妊薬の需要がさらに高まっています。したがって、上記の要因は予測期間のOTC医薬品市場の明るい成長見通しを示しています。

しかし、薬物乱用のためのOTC医薬品の誤用や、OTC医薬品の偽造の可能性、副作用の可能性は、OTC医薬品市場の成長抑制要因となる可能性があります。

上記の要因に加えて、OTC医薬品市場はCOVID-19パンデミックによるロックダウンの影響を受けました。COVID-19パンデミック中、この特定の市場は高い製品需要を維持していたにもかかわらず、サプライチェーンに大きな混乱が生じ、避妊薬、鎮痛薬、アレルギー薬などの製品は、ロックダウンの初期段階において生産がわずかに減少しました。さらに、COVID-19の軽症例に伴うインフルエンザのような症状により、パラセタモールなどのOTC解熱剤の需要が大幅に増加しました。パンデミック中にこうした製品の需要が増加したとはいえ、製造能力の低下、ロジスティクスの課題、高い調達コストといったサプライチェーンの混乱により、供給面は大きな影響を受けました。しかし、パンデミック後のシナリオは、完全な生産能力での活動再開がサプライチェーンの復旧に役立つため、OTC医薬品市場にとって収益生成の好機となる環境がもたらされ、予測期間（2024年～2030年）におけるOTC医薬品市場の市場見通しが向上します。

当レポートでは、世界のOTC医薬品市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 OTC医薬品市場レポートのイントロダクション

第2章 OTC医薬品市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制と特許の分析

• 米国
• 欧州
• 日本
• 中国

第4章 OTC医薬品市場の主な要因の分析

• OTC医薬品市場の促進要因
• OTC医薬品市場の抑制要因と課題
• OTC医薬品市場の機会

第5章 OTC医薬品市場のポーターのファイブフォース分析

第6章 OTC医薬品市場に対するCOVID-19の影響分析

第7章 OTC医薬品市場のレイアウト

• 治療カテゴリ別
  • 咳、風邪、アレルギー
  • 胃腸
  • 鎮痛薬
  • その他
• 剤形別
  • 錠剤、粉末、カプセル
  • ドロップ
  • 局所クリーム、軟膏
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 OTC医薬品市場の企業と製品のプロファイル

• Johnson & Johsnon Services Inc
• BAYER AG
• Novartis
• sanofi-aventis U.S. LLC
• Pfizer Inc
• GlaxoSmithKline plc
• Cipla Inc
• Piramal Enterprises Limited
• Duramed Pharmaceuticals, Inc
• Glenmark Pharmaceuticals
• Innovus Pharmaceuticals, Inc
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc
• Reckitt Benckiser Group PLC
• Afaxys Pharma, LLC
• FOUNDATION CONSUMER HEALTHCARE
• Alcon Inc

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Over-The-Counter Drugs Market
• Table 3: Over-The-Counter Drugs Market in Global (2021-2030)
• Table 4: Over-The-Counter Drugs Market in Global by Therapeutic Category (2021-2030)
• Table 5: Over-The-Counter Drugs Market in Global by Formulation (2021-2030)
• Table 6: Over-The-Counter Drugs Market in Global by Distribution Channel (2021-2030)
• Table 7: Over-The-Counter Drugs Market in Global by Geography (2021-2030)
• Table 8: Over-The-Counter Drugs Market in North America (2021-2030)
• Table 9: Over-The-Counter Drugs Market in North America by Country (2021-2030)
• Table 10: Over-The-Counter Drugs Market in the US (2021-2030)
• Table 11: Over-The-Counter Drugs Market in Canada (2021-2030)
• Table 12: Over-The-Counter Drugs Market in Mexico (2021-2030)
• Table 13: Over-The-Counter Drugs Market in Europe (2021-2030)
• Table 14: Over-The-Counter Drugs Market in Europe by Country (2021-2030)
• Table 15: Over-The-Counter Drugs Market in France (2021-2030)
• Table 16: Over-The-Counter Drugs Market in Germany (2021-2030)
• Table 17: Over-The-Counter Drugs Market in the United Kingdom (2021-2030)
• Table 18: Over-The-Counter Drugs Market in Italy (2021-2030)
• Table 19: Over-The-Counter Drugs Market in Spain (2021-2030)
• Table 20: Over-The-Counter Drugs Market in Russia (2021-2030)
• Table 21: Over-The-Counter Drugs Market in Rest of Europe (2021-2030)
• Table 22: Over-The-Counter Drugs Market in APAC (2021-2030)
• Table 23: Over-The-Counter Drugs Market in APAC by Country (2021-2030)
• Table 24: Over-The-Counter Drugs Market in China (2021-2030)
• Table 25: Over-The-Counter Drugs Market in Japan (2021-2030)
• Table 26: Over-The-Counter Drugs Market in India (2021-2030)
• Table 27: Over-The-Counter Drugs Market in Australia (2021-2030)
• Table 28: Over-The-Counter Drugs Market in South Korea (2021-2030)
• Table 29: Over-The-Counter Drugs Market in Rest of APAC (2021-2030)
• Table 30: Over-The-Counter Drugs Market in Rest of World (2021-2030)
• Table 31: Over-The-Counter Drugs Market in RoW by Region (2021-2030)
• Table 32: Over-The-Counter Drugs Market in Middle East (2021-2030)
• Table 33: Over-The-Counter Drugs Market in Africa (2021-2030)
• Table 34: Over-The-Counter Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Over-The-Counter Drugs Market
• Figure 3: Over-The-Counter Drugs Market in Global (2021-2030)
• Figure 4: Over-The-Counter Drugs Market in Global by Therapeutic Category (2021-2030)
• Figure 5: Over-The-Counter Drugs Market in Global by Formulation (2021-2030)
• Figure 6: Over-The-Counter Drugs Market in Global by Distribution Channel (2021-2030)
• Figure 7: Over-The-Counter Drugs Market in Global by Geography (2021-2030)
• Figure 8: Over-The-Counter Drugs Market in North America (2021-2030)
• Figure 9: Over-The-Counter Drugs Market in North America by Country (2021-2030)
• Figure 10: Over-The-Counter Drugs Market in the US (2021-2030)
• Figure 11: Over-The-Counter Drugs Market in Canada (2021-2030)
• Figure 12: Over-The-Counter Drugs Market in Mexico (2021-2030)
• Figure 13: Over-The-Counter Drugs Market in Europe (2021-2030)
• Figure 14: Over-The-Counter Drugs Market in Europe by Country (2021-2030)
• Figure 15: Over-The-Counter Drugs Market in France (2021-2030)
• Figure 16: Over-The-Counter Drugs Market in Germany (2021-2030)
• Figure 17: Over-The-Counter Drugs Market in the United Kingdom (2021-2030)
• Figure 18: Over-The-Counter Drugs Market in Italy (2021-2030)
• Figure 19: Over-The-Counter Drugs Market in Spain (2021-2030)
• Figure 20: Over-The-Counter Drugs Market in Russia (2021-2030)
• Figure 21: Over-The-Counter Drugs Market in Rest of Europe (2021-2030)
• Figure 22: Over-The-Counter Drugs Market in APAC (2021-2030)
• Figure 23: Over-The-Counter Drugs Market in APAC by Country (2021-2030)
• Figure 24: Over-The-Counter Drugs Market in China (2021-2030)
• Figure 25: Over-The-Counter Drugs Market in Japan (2021-2030)
• Figure 26: Over-The-Counter Drugs Market in India (2021-2030)
• Figure 27: Over-The-Counter Drugs Market in Australia (2021-2030)
• Figure 28: Over-The-Counter Drugs Market in South Korea (2021-2030)
• Figure 29: Over-The-Counter Drugs Market in Rest of APAC (2021-2030)
• Figure 30: Over-The-Counter Drugs Market in Rest of World (2021-2030)
• Figure 31: Over-The-Counter Drugs Market in RoW by Region (2021-2030)
• Figure 32: Over-The-Counter Drugs Market in Middle East (2021-2030)
• Figure 33: Over-The-Counter Drugs Market in Africa (2021-2030)
• Figure 34: Over-The-Counter Drugs Market in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Over The Counter Drugs Market By Therapeutic Category (Cough, Cold & Allergy, Gastrointestinal, Analgesics, Dermatological, And Others), By Formulation (Tablets, Powders & Capsules, Drops, Topical Creams & Ointments, And Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, And Others), and by geography is expected to grow at an appreciable CAGR forecast till 2030 owing to the rapid switch of prescrpition durgs (RX ) to OTC status as well as increasing prevalence of various indications resulting in incidents of acute and chronic pains leading to extensive use of OTC drugs

The global over-the-counter (OTC) drugs market was valued at USD 151.15 billion in 2023, growing at a CAGR of 5.93% during the forecast period from 2024 to 2030 to reach USD 213.08 billion by 2030. The OTC drugs market is witnessing an explosion in product demand owing to numerous reasons such as the surge in the prevalence of different indications resulting in pain leading to growing demand for analgesics. Moreover, growing prevalence of gastrointestinal issues is another key factor contributing in the growth of OTC gastrointestinal drugs. Besides the factors stated above, the rapid switch from prescription to OTC status of various medication is also expected to play a key role in establishing an upward growth trend in the OTC drugs market during the forecast period from 2024 to 2030.

OTC Drugs Market Dynamics:

One of the primary factors driving the over-the-counter drugs market growth is the upsurge in the use of analgesics due to increase in various modalities affecting the musculoskeletal system cause problems such as arthritis, back pain, fibromyalgia among other indications such as menstrual cramps, headaches etcetera. For instance, as per the Rheumatoid Arthritis Network (2023), in 2022, 350 million people suffer from arthritis across the globe. Furthermore, as per the National Health Service UK (2023), fibromyalgia affects one in 20 people across the globe. Analgesics are a class of medication specifically aimed at providing pain relief. For arthritis, certain OTC pain relievers such as acetaminophen (Tylenol in the US) are actively consumed. Other OTC drugs pain relievers include ibuprofen or naproxen sodium. Besides analgesics, another popular category of OTC drugs include antipyretics which also include acetaminophen, ibuprofen, and dexibuporfen. Considering the growing prevalence of musculoskeletal ailments and the growing need for pain management is expected to drive the demand for OTC analgesic drugs in coming years, thereby driving the overall market for over the counter drugs during the forecast period from 2024-2030.

Another prominent factor responsible for the increasing demand of OTC drugs is the upsurge in cases of unintended pregnancies across the globe, which is expected to influence the demand for over the counter emergency contraception pills during the forecast period. For instance, as per the data provided by the World Health Organization (2023), 4 million women living in low and middle-income countries have unintended pregnancies annually across the globe. This leads to 25 million unsafe abortions and 47,000 maternal deaths every year globally. Modern methods of contraception have a vital role in preventing unintended pregnancies. The United Nation's Department of Economic and Social Affairs 2019 statistics mentioned that approximately 922 million women of reproductive age (or their partners) use contraception methods comprising various products of which emergency contraceptive pills are one of the most common and reliable sources for avoiding unintended pregnancies. Moreover, due to the COVID-19 pandemic, other alternatives available as methods of contraception such as intrauterine devices and contraceptive patches among others were not as easily accessible which further raised the demand for OTC emergency contraceptive pills among users. Therefore, the factors mentioned above indicate towards a positive growth outlook for the over the counter drugs market during the forecast period.

However, misuse of OTC drugs for substance abuse, the probability of counterfeiting of OTC drugs, and possibility of adverse drug reactions may prove to be deterrents to over-the-counter drugs market growth.

Besides the above-mentioned factors, the over the counter market was impacted by the imposition of the lockdown due to the COVID-19 pandemic. Even though this specific market maintained a high product demand during the COVID-19 pandemic, there was a significant disruption in supply chain wherein products such as contraceptive pills, analgesics, and allergy medication witnessed a slight reduction in production in the initial phase of the lockdown. Additionally, due to the flu-like symptoms associated with the milder cases of the COVID-19 infection, there was a significant increase in the demand for OTC antipyretics such as paracetamol. Even though the demand for such products did increase during the pandemic, the supply aspect was severely affected due to disruption in supply chain such as decreased manufacturing capacity, logistic challenges, and high procurement costs. Although, the post-pandemic scenario provides an opportune environment for revenue generation for the OTC drugs market due to the resumption of activities in full capacity helping in the restoration of supply chain thereby improving the market outlook for the over the counter drugs market during the forecast period (2024-2030).

Over the Counter (OTC) Drugs Market Segment Analysis:

Over The Counter Drugs Market by Therapeutic Category (Cough, Cold, and Allergy, Gastrointestinal, Analgesics, Dermatological, and Others), by Formulation (Tablets, Powders, and Capsules, Drops, Topical Creams and Ointments, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapeutic category type segment of the over the counter drugs market, analgesics drugs were estimated to account for significant revenue share in the year 2023. This can be attributed to the rising prevalence of indications that result in pain. Accessing analgesics without prescription is an added advantage for consumers as it allows consumers to address pain without having to go to a doctor to procure a prescription. As per the U.S. National Library of Medicine (2023), approximately 25 billion doses of acetaminophen are sold alone in the United States every year. Furthermore, the rising prevalence of indications resulting in pain such as headaches, minor injuries, among others are also expected to contribute in the growing demand for OTC drugs in forthcoming years.

North America is expected to dominate the overall Over the Counter Drugs Market:

Among all the regions, North America is projected to amass the largest share in revenue generation in the OTC drugs market. Some of the factors responsible for the growth of the North America over the counter drugs market is the number of switches from Rx to OTC status for various drugs, growing preference of OTC drugs over prescription drugs, comparatively less stringent regulatory guidelines for marketing approvals among others.

One of the prominent markets in the North American region is the United States. As per the Allergy and Asthma Foundation of America (2023), allergies are the sixth leading cause of chronic illness in the United States. The source further mentioned that over 50 million Americans experience various types of allergies each year. Additionally, as per Food Allergy and Education (2023), 32 million people have food allergies across the country. Furthermore, considering the high prevalence of food allergies in the country, the US Food and Drug Administration (FDA) classifies 8 major food items as common allergens as per the Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA). Additionally, in April, 2022, the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act was signed into law, declaring sesame as the 9th major food allergen recognized by the United States. Antihistamines are popular medication for allergies which are available over the counter. Some of the over the counter antihistamine drugs include brompheniramine, cetirizine, loratadine, clemastine among others. Therefore, the rise in prevalence of allergies in the country is expected to boost the demand for OTC antihistamines thereby driving the OTC drugs market in the North American region.

Additionally, the extensive switch of the Rx medication to OTC status is another factor driving the market growth in the North American region. For instance, in March 2022, Nasonex 24HR Allergy (mometasone furoate) nasal spray was given the OTC status by the US FDA. Moreover, the rising healthcare costs is expected to add to the demand for the OCT drugs as they cost significantly less than prescription drugs. Thus all the factors stated above are predicted to aid in the growth of the North America OTC drugs market during the forecast period.

Over the Counter Drugs Market Key Players:

Some of the key market players operating in the OTC drugs market includes Johnson & Johsnon Services Inc, BAYER AG, Novartis, sanofi-aventis U.S. LLC., Pfizer Inc, GlaxoSmithKline plc., Cipla Inc., Piramal Enterprises Limited, Duramed Pharmaceuticals, Inc, Glenmark Pharmaceuticals., Dr. Reddy's Laboratories, Innovus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc, Reckitt Benckiser Group PLC, Afaxys Pharma, LLC, FOUNDATION CONSUMER HEALTHCARE, Alcon Inc and others.

Recent Developmental Activities In Over the Counter Drugs Market:

In December 2022, the US Food and Drug Administration approved the prescription drug Lastacaft (alcaftadine ophthalmic solution), 0.25% to over-the counter drug.

In June 2022, Bayer received the regulatory approval from the US FDA for their product Asepro Allergy as an OTC drug for temporary relief from nasal congestion, itch and runny nose, and other respiratory allergies.

In July 2020, Alcon Inc received the approval from the US FDA for Pataday Once Daily Relief Extra Strength(olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo®, has been approved by the Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the United States.

Key Takeaways from Over the Counter Drugs Market Report Study

• Market size analysis for current OTC drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the OTC drugs market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global OTC drugs market.
• Various opportunities available for the other competitors in the OTC drugs market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current OTC drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for OTC drugs market growth in the coming future?

Target Audience who can be benefited from this Over the Counter Drugs Market Report Study

• OTC drugs products providers
• Research organizations and consulting companies
• OTC drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in OTC drugs
• Various end users who want to know more about the OTC drugs market and latest technological developments in the OTC drugs market.

Frequently Asked Questions for Over the Counter Drugs Market:

1. What are OTC Drugs?

Over-the-counter (OTC) drugs are essentially non-prescription drugs which can be obtained by consumers without any prescription from healthcare professionals. These drugs are also regulated by the concerned regulatory authorities and are efficient and safe to use.

2. What is the market for Global OTC Drugs?

The global over-the-counter (OTC) drugs market was valued at USD 151.15 billion in 2023, growing at a CAGR of 5.93% during the forecast period from 2024 to 2030 to reach USD 213.08 billion by 2030.

3. What are the drivers for Global Over-The-Counter Drugs Market?

The OTC drugs market is witnessing an explosion in product demand due to numerous reasons such as the surge in the prevalence of different indications resulting in pain leading to growing demand for analgesics. Moreover, growing prevalence of gastrointestinal issues is another factor contributing in the growth of OTC gastrointestinal drugs. Besides the factors stated above, the rapid switch from prescription to OTC status of various medication is also expected to play a key role in establishing an upward growth trend in the OTC drugs market during the forecast period from 2024 to 2030.

4. Who are the key players operating in Global Over-The-Counter Drugs Market?

Some of the key market players operating in the OTC drugs market includes Johnson & Johsnon Services Inc, BAYER AG, Novartis, sanofi-aventis U.S. LLC., Pfizer Inc, GlaxoSmithKline plc., Cipla Inc., Piramal Enterprises Limited, Duramed Pharmaceuticals, Inc, Glenmark Pharmaceuticals., Dr. Reddy's Laboratories, Innovus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc, Reckitt Benckiser Group PLC, Afaxys Pharma, LLC, FOUNDATION CONSUMER HEALTHCARE, Alcon Inc and others.

5. Which region has the highest share in Over-The-Counter Drugs market?

Among all the regions, North America is projected to amass the largest share in revenue generation in the OTC drugs market. Some of the factors responsible for the growth of the North America over the counter drugs market is the number of switches from Rx to OTC status for various drugs, growing preference of OTC drugs over prescription drugs, comparatively less stringent regulatory guidelines for marketing approvals among others.

Table of Contents

1.Over-The-Counter Drugs Market Report Introduction

2.Over-The-Counter Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Over-The-Counter Drugs Market Key Factors Analysis

• 4.1. Over-The-Counter Drugs Market Drivers
  • 4.1.1. Rising Incidence of Indications/Injuries Resulting in Acute Pain
  • 4.1.2. Increase in Prevalence of Gastrointestinal Issues
  • 4.1.3. Surge in Number of Rx to OTC Status Switch of Drugs
• 4.2. Over-The-Counter Drugs Market Restraints and Challenges
  • 4.2.1. Possibility of Substance Abuse of OTC Drugs
  • 4.2.2. Possibility of Adverse Drug Reactions
  • 4.2.3. Counterfeiting of OTC Drugs
• 4.3. Over-The-Counter Drugs Market Opportunities
  • 4.3.1. Widening the Supply Chain Network in Emerging Economies

5. Over-The-Counter Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Over-The-Counter Drugs Market

7. Over-The-Counter Drugs Market Layout

• 7.1. By Therapeutic Category
  • 7.1.1. Cough, Cold, & Allergy
  • 7.1.2. Gastrointestinal
  • 7.1.3. Analgesics
  • 7.1.4. Others
• 7.2. By Formulation
  • 7.2.1. Tablets, Powders, & Capsules
  • 7.2.2. Drops
  • 7.2.3. Topical Creams & Ointments
  • 7.2.4. Others
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
  • 7.3.5. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. North America Over-The-Counter Drugs Market, by Country
    • 7.4.1.4.1. United States
    • 7.4.1.4.2. Canada
    • 7.4.1.4.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. Europe Over-The-Counter Drugs Market, by Country
    • 7.4.2.1.1 France
    • 7.4.2.1.2 Germany
    • 7.4.2.1.3 United Kingdom
    • 7.4.2.1.4 Italy
    • 7.4.2.1.5 Spain
    • 7.4.2.1.6 Russia
    • 7.4.2.1.7 Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. Asia-Pacific Over-The-Counter Drugs Market, by Country
    • 7.4.3.4.1. China
    • 7.4.3.4.2. Japan
    • 7.4.3.4.3. India
    • 7.4.3.4.4. Australia
    • 7.4.3.4.5. South Korea
    • 7.4.3.4.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. RoW Over-The-Counter Drugs Market, by Region
    • 7.4.4.4.1. Middle East
    • 7.4.4.4.2. Africa
    • 7.4.4.4.3. South America

8. Over-The-Counter Drugs Market Company and Product Profiles

• 8.1. Johnson & Johsnon Services Inc
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. BAYER AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Novartis
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. sanofi-aventis U.S. LLC
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. GlaxoSmithKline plc
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Cipla Inc
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Piramal Enterprises Limited
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Duramed Pharmaceuticals, Inc
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Glenmark Pharmaceuticals
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Innovus Pharmaceuticals, Inc
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Dr. Reddy's Laboratories
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Teva Pharmaceutical Industries Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Viatris Inc
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Reckitt Benckiser Group PLC
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Afaxys Pharma, LLC
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. FOUNDATION CONSUMER HEALTHCARE
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Alcon Inc
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us